Daily Pharma News - 5 October 2026

CDSCO Proposes Red Box Warnings on Cough Syrup Labels: No Use Below Age 4, Ban on Baby Pictures

India's Central Drugs Standard Control Organisation (CDSCO) drugs panel has proposed bold red warnings on cough syrup labels explicitly barring use in children below the age of four, alongside a ban on infant or toddler imagery on cough syrup packs. The proposal will now go to the Drugs Technical Advisory Board (DTAB) for approval, followed by a gazette notification to make the labelling change legally binding.

For pharmacy students, this is a landmark labelling intervention in paediatric drug safety. Cough and cold formulations have a troubled history in paediatric pharmacovigilance in India, and the move reflects a growing regulatory consensus that label design itself is a patient-safety tool. The red-warning format - the Indian equivalent of a boxed warning - is designed to be impossible to miss at the dispensing counter, which places a direct responsibility on pharmacists to counsel parents and refuse inappropriate paediatric dispensing. Watch the DTAB's decision and the gazette notification date closely; label-change timelines are a favourite question in regulatory affairs exams.

Teneligliptin Safety Alert: CDSCO Directs Package Insert Update for Bullous Pemphigoid ADR

CDSCO has directed manufacturers of the diabetes drug teneligliptin - marketed in India under brand names including Tenglyn and Teniva - to add bullous pemphigoid, a rare autoimmune blistering skin disease, as an adverse drug reaction (ADR) in their package inserts. The directive follows pharmacovigilance reviews that flagged case reports linking the DPP-4 inhibitor to this serious dermatological condition.

This is post-marketing surveillance working exactly as designed. Teneligliptin, a gliptin widely prescribed for type 2 diabetes mellitus in India, went through standard pre-approval trials, but rare ADRs like bullous pemphigoid - which presents with tense, intensely itchy blisters - typically only emerge once a drug is used in large, diverse real-world populations. For pharmacy students, the learning point is practical: package inserts are living documents, pharmacists must stay current with CDSCO safety alerts, and suspected ADRs should be reported through the Pharmacovigilance Programme of India (PvPI). A patient on teneligliptin who develops unexplained blistering needs urgent dermatological referral, and the updated insert now gives that counselling a regulatory backbone.

TG-SAFE Audit Shock: 70% of Hyderabad Pharmacies Let Unregistered Staff Dispense Medicines

An audit by Telangana's TG-SAFE (Taskforce for Safety Action and Enforcement) has found that 70 percent of pharmacies in Hyderabad allow unregistered persons to dispense medicines. The findings point to widespread risks: wrong dosages, unsafe over-the-counter sales of antibiotics, analgesics and antidiabetics, and a breakdown of the professional safeguards that the Pharmacy Act, 1948 was designed to guarantee.

This story cuts straight to the heart of pharmacy practice in India. Dispensing by unqualified staff is not a victimless shortcut - it fuels antimicrobial resistance through inappropriate antibiotic sales, exposes diabetic patients to dosage errors, and erodes public trust in the profession. For B.Pharm and Pharm.D students, the message is twofold: first, understand that a registered pharmacist's physical presence and supervision during dispensing is a legal and ethical obligation, not a formality; second, recognise that enforcement drives like TG-SAFE are reshaping the employment landscape, with qualified pharmacists becoming harder to substitute. This is the kind of current-affairs case study that belongs in both community pharmacy practicals and hospital pharmacy discussions.

NMPA China Clears Kexing Biopharm's Anti-TL1A Monoclonal Antibody GB20 for IBD Clinical Trials

China's National Medical Products Administration (NMPA) has cleared Kexing Biopharm's investigational anti-TL1A monoclonal antibody, GB20, to enter clinical trials for inflammatory bowel disease (IBD). The antibody targets tumour necrosis factor-like ligand 1A (TL1A), suppressing intestinal inflammation and delaying fibrosis in Crohn's disease and ulcerative colitis - the two major forms of IBD.

TL1A has emerged as one of the most exciting targets in gastroenterology drug development, with the pathway implicated not just in inflammation but in the fibrotic strictures that make Crohn's disease so difficult to treat. GB20 now joins a global race that includes several Western anti-TL1A candidates, and its NMPA clearance signals China's growing ambitions in innovative biologics. The India angle matters here: IBD incidence is rising sharply among young Indians, and today's pharmacy students will almost certainly counsel patients on biologic therapies - from established anti-TNF agents like infliximab to newer mechanisms like anti-TL1A - during their careers. Understanding monoclonal antibody nomenclature, mechanism and immunogenicity is no longer optional knowledge.

Russian Drone Strike Destroys Indian-Run Kusum Group Pharma Plant in Sumy, Ukraine: Supply Chain Shock

Russian drones struck the Sumy, Ukraine manufacturing plant of the Indian-run Kusum Group on 4 October, killing one worker and injuring three others. The plant, which had continued operating through the war, suffered damage estimated at about Rs 400 crore. The Ukrainian embassy confirmed the casualties and the scale of destruction.

Beyond the human tragedy, this is a stark lesson in pharmaceutical supply chain vulnerability. Kusum Group is an Indian pharmaceutical company with a significant manufacturing footprint in Ukraine, and its Sumy facility supplied medicines in a country already under wartime strain. For pharmacy students, the takeaway is strategic: drug availability is not just a manufacturing question but a geopolitical one. Supply chain resilience, dual sourcing of active pharmaceutical ingredients (APIs), and business continuity planning are now core competencies in pharmaceutical management - and Indian companies' deep global footprint means events thousands of kilometres away can ripple back into domestic medicine availability.

Gilead's Obeldesivir: Oral Antiviral Tested as Post-Exposure Prophylaxis in DR Congo Ebola Outbreak

More than 250 people in the Democratic Republic of Congo have enrolled in the EBO-PEP clinical trial, which is testing Gilead's obeldesivir - an oral antiviral pill - as post-exposure prophylaxis (PEP) against Bundibugyo virus, the ebolavirus behind the current outbreak. The outbreak has reportedly caused around 8,300 cases and 4,000 deaths, making it one of the deadliest Ebola outbreaks on record.

Obeldesivir, an oral nucleoside analogue related to remdesivir, could transform Ebola outbreak response if the trial succeeds. Current Ebola countermeasures rely heavily on monoclonal antibody treatments and ring vaccination, both of which demand cold-chain logistics and trained personnel - scarce resources in outbreak zones. A simple oral pill taken after exposure would be dramatically easier to deploy to contacts of cases. For pharmacy students, this is a masterclass in antiviral drug development: repurposing nucleoside analogue chemistry across viral families, the logic of PEP trial design, and the regulatory pathways for emergency-use antivirals. Watch the EBO-PEP results - they may define the next chapter of filovirus therapeutics.

Conclusion

Today's news ties together the full arc of a pharmacist's world. At home, CDSCO tightened the safety net twice - red warnings to protect children from cough syrups, and a package insert update to warn teneligliptin users about a rare skin reaction - while Telangana's TG-SAFE audit showed why qualified pharmacists must actually be the ones behind the counter. Abroad, China's NMPA opened the door for a promising anti-TL1A biologic in IBD, Gilead's obeldesivir pill offered hope against Ebola in Congo, and a Russian drone strike on an Indian-run plant in Ukraine reminded everyone that medicine supply chains are fragile in a fractured world. For pharmacy students, the common thread is responsibility: regulation only works when professionals enforce it, innovation only helps when it reaches patients, and every one of these stories - from a label change to a clinical trial - will eventually land at a dispensing counter near you.

References

← All daily news